Sagar Lonial, MD, on Monoclonal Antibodies in Multiple Myeloma

2014 ASH Annual Meeting

Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 302, “Final Results for the 1703 Phase Ib/II Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma,” presented by Paul G. Richardson, MD; abstract 84, “Safety and Efficacy of Daratumumab With Lenalidomide and Dexamethasone in Relapsed or Relapsed/ Refractory Multiple Myeloma,” presented by Torben Plesner, MD; and “A Phase Ib Dose Escalation Trial of SAR650984 (Anti–CD-38 mAb) in Combination With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma,” presented by Thomas G. Martin III, MD.

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinical trials: different doses of daunorubicin for AML; comparing azacitidine plus lenolidomide to vorinostat vs azacitidine monotherapy in MDS and CMML; and sorafenib vs placebo in addition to standard treatment for AML.

Lymphoma

Laurie Sehn, MD

Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.

Lymphoma

Bertrand Coiffier, MD, PhD

Mar

Today In Oncology

Sagar Lonial, MD, on Monoclonal Antibodies in Multiple Myeloma

Related Videos

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Matthew Lunning, DO, on Ublituximab Plus TGR-1202 in Lymphoma

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer

SABCS 2025: Top Picks From a Breast Cancer Specialist

Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer